Thrombopoietin (TPO) mimetics led to fewer bleeding events than placebo in patients with myelodysplastic syndrome (MDS), according to a Cochrane review of 8 studies involving 746 individuals. However, there appeared to be no mortality differences. Among the specific findings, based on moderate quality evidence:
- TPO mimetics probably decrease the number of patients having bleeding events. 71% of patients taking placebo experienced such events, vs 66% of those taking TPO mimetics.
- No difference was seen in terms of mortality, transformation to acute myeloid leukemia, transfusion requirement, adverse events, and serious adverse events.
- No trial evaluated quality of life.
Dodillet H, Kreuzer K, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database of Syst Rev. 2017, Issue 9. Art. No.: CD009883. doi:10.1002/14651858.CD009883.pub2.
This Week's Must Reads
Must Reads in AML
Azacitidine in Lower-Risk MDS Shows Promise, Oncologist; ePub 2017 Nov 8; Komrokji, et al
Clostridium Difficile Infection in People with MDS, World J Clin Oncol; 2017 Oct 10; Shaht, et al
Survival in Azacitidine-Treated Patients Assessed, Leuk Res; 2017 Oct 27; Sébert, Komrokji et al
Use This to Evaluate MRD Prior to Allo-SCT, Leuk Res; 2017 Dec; Candoni, De Marchi, et al
Detecting Minimal Residual Disease in AML, Curr Hematol Malig Rep; ePub 2017 Nov 2; Zhou, et al